|
市場調査レポート
商品コード
1609740
日本の細胞および遺伝子治療市場レポート：治療タイプ、適応症、デリバリーモード、エンドユーザー、地域別、2025年～2033年Japan Cell and Gene Therapy Market Report by Therapy Type, Indication, Delivery Mode, End User, and Region 2025-2033 |
||||||
カスタマイズ可能
|
|||||||
| 日本の細胞および遺伝子治療市場レポート：治療タイプ、適応症、デリバリーモード、エンドユーザー、地域別、2025年～2033年 |
|
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 121 Pages
納期: 5～7営業日
|
- 全表示
- 概要
- 目次
日本の細胞および遺伝子治療市場の市場規模は2024年に7億2,700万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに20億1,600万米ドルに達し、2025年から2033年の間に12％の成長率（CAGR）を示すと予測しています。慢性疾患や遺伝性疾患の増加により、これらのヘルスケア課題に対処できる高度な治療薬への需要が高まっており、これが主に市場成長を牽引しています。
本レポートで扱う主な質問
- 日本の細胞および遺伝子治療市場はこれまでどのように推移し、今後どのように推移するのか？
- COVID-19が日本の細胞および遺伝子治療市場に与えた影響は？
- 日本の細胞および遺伝子治療市場の治療タイプ別の内訳は？
- 日本の細胞および遺伝子治療市場の適応症別の内訳は？
- 日本の細胞および遺伝子治療市場の投与形態別の内訳は？
- 日本の細胞および遺伝子治療市場のエンドユーザー別の内訳は？
- 日本の細胞および遺伝子治療市場のバリューチェーンにはどのような段階がありますか？
- 日本の細胞および遺伝子治療の主な促進要因と課題は何か？
- 日本の細胞および遺伝子治療市場の構造と主要プレーヤーは？
- 日本の細胞および遺伝子治療市場における競合の程度は？
目次
第1章 序文
第2章 調査範囲と調査手法
- 調査の目的
- ステークホルダー
- データソース
- 市場推定
- 調査手法
第3章 エグゼクティブサマリー
第4章 日本の細胞および遺伝子治療市場：イントロダクション
- 概要
- 市場力学
- 業界動向
- 競合情報
第5章 日本の細胞および遺伝子治療市場情勢
- 過去および現在の市場動向（2019年～2024年）
- 市場予測（2025-2033）
第6章 日本の細胞および遺伝子治療市場：治療タイプ別の内訳
- 細胞療法
- 遺伝子治療
第7章 日本の細胞および遺伝子治療市場：適応症別の内訳
- 心血管疾患
- 腫瘍疾患
- 遺伝性疾患
- 感染症
- 神経疾患
- その他
第8章 日本の細胞および遺伝子治療市場：デリバリーモード別の内訳
- 生体内
- 生体外
第9章 日本の細胞および遺伝子治療市場：エンドユーザー別の内訳
- 病院
- がんケアセンター
- 製薬・バイオテクノロジー企業
- その他
第10章 日本の細胞および遺伝子治療市場：競合情勢
- 概要
- 市場構造
- 市場プレーヤーのポジショニング
- 主要成功戦略
- 競合ダッシュボード
- 企業評価象限
第11章 主要企業のプロファイル
第12章 日本の細胞および遺伝子治療市場：業界分析
- 促進要因・抑制要因・機会
- ポーターのファイブフォース分析
- バリューチェーン分析
第13章 付録
Japan cell and gene therapy market size reached USD 727 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,016 Million by 2033, exhibiting a growth rate (CAGR) of 12% during 2025-2033. The increasing adoption of chronic and genetic diseases is propelling the demand for advanced therapies capable of addressing these healthcare challenges, which is primarily driving the market growth.
Cell and gene therapy are cutting-edge medical approaches that hold immense promise for the treatment of various diseases and conditions. In essence, cell therapy involves the transplantation or manipulation of living cells to replace or repair damaged or malfunctioning tissues within the body. This can include the use of stem cells to regenerate damaged organs or tissues. On the other hand, gene therapy focuses on modifying or correcting faulty genes responsible for causing diseases. This can be achieved by introducing, replacing, or repairing specific genes within a patient's cells. Both cell and gene therapy are at the forefront of personalized medicine, offering the potential to provide targeted, individualized treatments that can address the root causes of diseases, rather than just managing their symptoms. These innovative therapies have shown remarkable success in clinical trials and are paving the way for a new era in healthcare, with the potential to revolutionize the treatment of genetic disorders, cancer, and a range of other challenging medical conditions.
Japan Cell and Gene Therapy Market Trends:
The Japan cell and gene therapy market is rapidly emerging as a dynamic and promising sector within the country's healthcare landscape. With an aging population and a growing burden of chronic diseases, there is a heightened demand for innovative treatments that can offer long-term solutions. Cell and gene therapy have gained significant attention and investment in Japan due to their potential to address unmet medical needs. Japanese researchers and biopharmaceutical companies have been actively engaged in developing novel therapies using these cutting-edge technologies. Regulatory authorities in Japan have also taken steps to facilitate the clinical development and commercialization of cell and gene therapies, making it an attractive market for both domestic and international players. The market's growth is further fueled by collaborations between academia, industry, and healthcare providers, as well as the increasing adoption of precision medicine approaches. As a result, the Japan cell and gene therapy market is poised for continued expansion and is likely to play a pivotal role in the future of healthcare in the country.
Japan Cell and Gene Therapy Market Segmentation:
Therapy Type Insights:
- Cell Therapy
- Stem Cell
- Non-Stem Cell
- Gene Therapy
Indication Insights:
- Cardiovascular Disease
- Oncology Disorder
- Genetic Disorder
- Infectious Disease
- Neurological Disorder
- Others
Delivery Mode Insights:
- In-Vivo
- Ex-Vivo
End User Insights:
- Hospitals
- Cancer Care Centers
- Pharmaceutical and Biotechnology Companies
- Others
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Key Questions Answered in This Report:
- How has the Japan cell and gene therapy market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the Japan cell and gene therapy market?
- What is the breakup of the Japan cell and gene therapy market on the basis of therapy type?
- What is the breakup of the Japan cell and gene therapy market on the basis of indication?
- What is the breakup of the Japan cell and gene therapy market on the basis of delivery mode?
- What is the breakup of the Japan cell and gene therapy market on the basis of end user?
- What are the various stages in the value chain of the Japan cell and gene therapy market?
- What are the key driving factors and challenges in the Japan cell and gene therapy?
- What is the structure of the Japan cell and gene therapy market and who are the key players?
- What is the degree of competition in the Japan cell and gene therapy market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Japan Cell and Gene Therapy Market - Introduction
- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence
5 Japan Cell and Gene Therapy Market Landscape
- 5.1 Historical and Current Market Trends (2019-2024)
- 5.2 Market Forecast (2025-2033)
6 Japan Cell and Gene Therapy Market - Breakup by Therapy Type
- 6.1 Cell Therapy
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Segmentation
- 6.1.3.1 Stem Cell
- 6.1.3.2 Non-Stem Cell
- 6.1.4 Market Forecast (2025-2033)
- 6.2 Gene Therapy
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
7 Japan Cell and Gene Therapy Market - Breakup by Indication
- 7.1 Cardiovascular Disease
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
- 7.2 Oncology Disorder
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
- 7.3 Genetic Disorder
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
- 7.4 Infectious Disease
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
- 7.5 Neurological Disorder
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
- 7.6 Others
- 7.6.1 Historical and Current Market Trends (2019-2024)
- 7.6.2 Market Forecast (2025-2033)
8 Japan Cell and Gene Therapy Market - Breakup by Delivery Mode
- 8.1 In-Vivo
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
- 8.2 Ex-Vivo
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
9 Japan Cell and Gene Therapy Market - Breakup by End User
- 9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
- 9.2 Cancer Care Centers
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
- 9.3 Pharmaceutical and Biotechnology Companies
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
- 9.4 Others
- 9.4.1 Historical and Current Market Trends (2019-2024)
- 9.4.2 Market Forecast (2025-2033)
10 Japan Cell and Gene Therapy Market - Competitive Landscape
- 10.1 Overview
- 10.2 Market Structure
- 10.3 Market Player Positioning
- 10.4 Top Winning Strategies
- 10.5 Competitive Dashboard
- 10.6 Company Evaluation Quadrant
11 Profiles of Key Players
- 11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
- 11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
- 11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
- 11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
- 11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events
12 Japan Cell and Gene Therapy Market - Industry Analysis
- 12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
- 12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
- 12.3 Value Chain Analysis
